Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

There is an unmet need to develop new, more effective and safe therapies for the aggressive forms of triple negative breast cancers (TNBCs). While up to 20% of women under 50 years of age with TNBC harbor germline mutations in BRCA1, and these tumors are sensitive to treatment with poly(ADP) ribose...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ha, Kyungsoo, Fiskus, Warren, Choi, Dong Soon, Bhaskara, Srividya, Cerchietti, Leandro, Devaraj, Santhana G. T., Shah, Bhavin, Sharma, Sunil, Chang, Jenny C., Melnick, Ari M., Hiebert, Scott, Bhalla, Kapil N.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4170637/
https://ncbi.nlm.nih.gov/pubmed/25026298
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items